# Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

> **NCT03052764** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 120 (actual)

## Conditions studied

- Urinary Bladder, Overactive
- Urinary Incontinence

## Interventions

- **BIOLOGICAL:** onabotulinumtoxinA
- **DRUG:** Placebo (saline)

## Key facts

- **NCT ID:** NCT03052764
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-12
- **Primary completion:** 2018-12-10
- **Final completion:** 2018-12-10
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2019-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03052764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03052764, "Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03052764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*